Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials

Contextualising the benefits and risks of anti‐amyloid therapy for patients with Alzheimer disease and their care team

“…For example, the MCID for CDR‐SB was estimated to be 0.54, 0.98 and 1.63 over a one‐year period for an individual with no cognitive impairment, mild cognitive impairment, and early Alzheimer disease respectively 20 . It may appear that the mAB trials fail to meet this threshold, but these values indicated meaningful thresholds for within‐patient progression, and not group‐level differences 8,21 . A personalised assessment of MCID (Box 2) may help frame whether mAB treatment would be beneficial.…”